The Prevention Grants funded by the ALS Association support translation research worldwide on amyotrophic lateral sclerosis (ALS), specifically with the goal of preventing or delaying the onset of ALS. Some areas of interest for this grant include:
- Improved tools for demonstrating a causative role of environmental exposures in a scientifically rigorous manner that is least burdensome to people with ALS
- Development of frameworks for determining the level of evidence required to translate knowledge of an environmental risk factor into a pharmaceutical, behavioral, or ecological intervention
- Preclinical or clinical drug development aimed at prevention of ALS, including efforts to treat prodromal syndromes such as mild motor impairment (MMI)
- Partnerships across FTD and other neurodegenerative and neuropsychiatric disease communities to mitigate ALS risk among different populations at elevated risk for ALS
- New studies leveraging existing population-based cohorts, to study both environmental risk factors for ALS, as well as MMI as a clinical syndrome that is prodromal to ALS
- Infrastructure to enable study of those at elevated risk for ALS including clinical cohorts and efforts designed to study potential interactions between genetic and environmental risk factors
- Any other proposal with the potential to prevent the onset of ALS
The grant is open to individuals with the competence to be principal investigators and may be based at either US or non-US research organizations, including industry. This funding provides $400,000 USD (including 10% indirect costs) for 2 years.
Letters of intent are due on May 17, 2023. Full applications are by invitation only and due on July 19, 2023.
July 19, 2023